In clinical practice, thrombopoietin receptor agonists (TPO-RAs), such as eltrombopag, have emerged as an effective treatment option for patients with refractory ITP by enhancing platelet production through the stimulation of megakaryocyte proliferation and differentiation [19, 20]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.